Reviving the Antibiotic Pipeline: How Can New Investments and Incentives Beat Superbugs?
October 19 at 3:30 pm PDT / 6:30 pm EDT
As antimicrobial resistance (AMR) continues to spread and become deadlier, potentially exacerbated by the COVID-19 pandemic, the need for new drugs has never been clearer. The antibiotic market continues to struggle from under investment and a lack of players needed to bring drugs through R&D to commercialization. While there have been positive signs in turning this around, including pull incentives and other forms of post-market support, more investment may be needed to bring drug companies back into antibiotic development. What models seem most promising? What lessons can we apply from other sectors' solutions to similar crises? And how can we foster international collaboration to jumpstart the antibiotic pipeline to combat the ever-growing threat of AMR?
General Assignment Reporter, STAT News
Chief Executive and Acting Chief Scientific Officer, Revagenix, Inc.
Co-founder and Chief Scientific Officer, Lytica Therapeutics
Chief Scientific Officer, Forge Therapeutics
Managing Partner, Adjuvant Capital